Vericel Corp. Stock
€40.80
Your prediction
Vericel Corp. Stock
Pros and Cons of Vericel Corp. in the next few years
Pros
Cons
Performance of Vericel Corp. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Vericel Corp. | -1.920% | -0.488% | 20.710% | 28.302% | 29.114% | 18.605% | -3.774% |
| Pacira Pharmaceuticals | -0.900% | -0.901% | 12.245% | 15.183% | 1.852% | -33.735% | -52.174% |
| Supernus Pharmaceuticals | -0.480% | -1.415% | 10.582% | 47.183% | -2.791% | 60.769% | 90.000% |
| Collegium Pharmaceutical Inc | -1.270% | 1.299% | 6.849% | 16.418% | -24.638% | 64.211% | 56.784% |
Comments
News
Vericel Stock Is Up 10%. Here's What This $402,000 Insider Sale Really Suggests
Michael Halpin, Chief Operating Officer of Vericel Corporation (NASDAQ:VCEL), reported the sale of 10,000 shares of Common Stock for a transaction value of approximately $402,000 on June 18, 2026
Vericel Revenue Jumped 20%. One Biotech Investor Just Reported Adding $63 Million More
Soleus Capital Management disclosed a significant buy of Vericel (NASDAQ:VCEL), adding 1,785,079 shares in the first quarter—an estimated $63.40 million trade based on quarterly average
Vericel Q1 Earnings Call Highlights
Vericel (NASDAQ:VCEL) reported record first-quarter revenue and raised its full-year 2026 outlook, citing strong growth across its MACI cartilage


